All eCQMs associated with PCPI(R) Foundation (PCPI[R])
| Year | Type | CMS eCQM ID | Measure Name |
|---|---|---|---|
| 2021 | EP/EC | CMS129v10 | Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients |
| 2018 | EP/EC | CMS129v7 | Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients |
| 2019 | EP/EC | CMS129v8 | Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients |
| 2020 | EP/EC | CMS129v9 | Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients |
| 2018 | EP/EC | CMS132v6 | Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures |
| 2019 | EP/EC | CMS132v7 | Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures |
| 2018 | EP/EC | CMS133v6 | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| 2019 | EP/EC | CMS133v7 | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| 2020 | EP/EC | CMS133v8 | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| 2021 | EP/EC | CMS133v9 | Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery |
| 2018 | EP/EC | CMS135v6 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| 2019 | EP/EC | CMS135v7 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| 2020 | EP/EC | CMS135v8 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| 2021 | EP/EC | CMS135v9 | Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD) |
| 2018 | EP/EC | CMS138v6 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
| 2019 | EP/EC | CMS138v7 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
| 2020 | EP/EC | CMS138v8 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
| 2021 | EP/EC | CMS138v9 | Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention |
| 2018 | EP/EC | CMS142v6 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |
| 2019 | EP/EC | CMS142v7 | Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care |